Early piribedil monotherapy of parkinson's disease: A planned seven-month report of the REGAIN study

Movement Disorders

Volumn 21, Issue 12, 2006, Pages 2110-2115

  Rascol, Olivier ^a   Dubois, Bruno ^b   Castro Caldas, Alexandre ^c   Senn, Stephen ^d   Del Signore, Susanna ^e   Lees, Andrew ^f  

^a INSERM   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c CATHOLIC UNIVERSITY OF PORTUGAL   (Portugal)

^d UNIVERSITY OF GLASGOW   (United Kingdom)

^e INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

^f ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

L dopa; Monotherapy; Parkinson's disease; Piribedil

Indexed keywords

DOMPERIDONE; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; PIRIBEDIL; PLACEBO;

ABDOMINAL PAIN; ADULT; AGED; ANXIETY; ARTICLE; CLINICAL OBSERVATION; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DETERIORATION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; EARLY INTERVENTION; FEMALE; GASTROINTESTINAL SYMPTOM; HALLUCINATION; HUMAN; HYPERTENSION; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MONOTHERAPY; MULTICENTER STUDY; NAUSEA; OPEN STUDY; ORTHOSTATIC HYPOTENSION; OUTCOME ASSESSMENT; PARKINSON DISEASE; PERIPHERAL EDEMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SCORING SYSTEM; SIDE EFFECT; SOMNOLENCE; TREATMENT DURATION; UNIFIED PARKINSON DISEASE RATING SCALE;

EID: 33846454323     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.21122     Document Type: Article

References (28)

1. Marsden CD, Parkes JD. Success and problems of long-term levodopa therapy in Parkinson's disease. Lancet 1977;1:345-349.
2. Poewe WH, Lees AJ, Stern GM. Low-dose L-dopa therapy in Parkinson's disease: a 6-year follow-up study. Neurology 1986; 36:1528-1530.
3. Marsden CD. Late levodopa failure: pathophysiology and management. In: Poewe W, Lees AJ, editors. Twenty years of madopar: new avenues. Basel: Editions Roche; 1994. p 65-76.
4. Rascol O, Goetz C, Koller W, Poewe W, Sampaio C. Treatment interventions for Parkinson's disease: an evidence based assessment. Lancet 2002;359:1589-1598.
5. Goetz CG, Poewe W, Rascol O, Sampaio C. Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004. Mov Disord 2005;20:523-539.
6. Creese I. Behavioural evidence of dopamine receptor stimulation by Piribedil (ET-495) and its metabolite S 584. Eur J Pharmacol 1974;28:55-58.
7. 3 autoreceptors control synthesis and release in mesolimbic, mesocortical and nigrostrial pathways. J Pharmacol Exp Ther 1995;275:899-913.
8. 2 receptors elicits prolactin secretion and catalepsy. J Pharmacol Exp Ther 1995;275:885-898.
9. Smith LA, Tel BC, Jackson MJ, et al. Repeated administration of Piribedil induces less dyskinesia than L-dopa in MPTP-treated common marmosets: a behavioural and biochemical investigation. Mov Disord 2002;17:887-901.
10. Rondot P, Bathien N, Ribadeau-Dumas JL. Indications of Piribedil in L-dopa-treated parkinsonian patients: physiopathologic implications. Adv Neurol 1975;9:373-381.
11. Ziegler M, Castro-Caldas A, Del Signore S, Rascol O. Efficacy of Piribedil as early combination to levodopa in patients with stable Parkinson's disease: a 6-month, randomized, placebo-controlled study. Mov Disord 2003;18:418-425.
12. Kwiecinski H, Fedorova N, Takats A, Ruzicka E, Jamrozik Z, Del Signore S. A multicenter trial of piribedil as early adjunct treatment for Parkinson's disease: Piribedil International Study Group (PISG). Neurology 2002;58(Suppl. 3):A163.
13. Castro-Caldas A, Delwaide P, Jost W, et al., the Parkinson-CONTROL Study Group. The Parkinson-CONTROL study, a 1-year randomized, double-blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with L-dopa in Parkinson's disease. Mov Disord 2006;21:500-509.
14. Ziegler M, Rondot P. Activité du piribédil dans la maladie de Parkinson: etude multicentrique. Press Med 1999;28:1414-1418.
15. Gibb WR, Lees AJ. The progression of idiopathic Parkinson's disease is not explained by age-related changes: clinical and pathological comparisons with post-encephatitic parkinsonian syndrome. Acta Neuropathol (Berl) 1987;73:195-201.
16. Hoehn MM, Yahr MD. Parkinson: onset progression and mortality. Neurology 1967;17:427-442.
17. Fahn S, Elton RL, members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Calne DB, editors. Recent Developments in Parkinson's Disease, vol. 2. London: Macmillan Health Care Information; 1987. p 153-163.
18. Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. N Engl J Med 2000;342:1484-1491.
19. Adler CH, Sethi KD, Hauser RA, et al. Ropinirole for the treatment of early Parkinson's disease. Neurology 1997;49:393-399.
20. Shannon KM, Bennet JP Jr, Friedman JH, the Pramipexole Study Group. Efficacy of Pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease. Neurology 1997;49:724-728.
21. Barone P, Bravi D, Bermejo-Pereira F, et al. Pergolide monotherapy in the treatment of early PD: a randomised, controlled study. Neurology 1999;53:573-579.
22. Parkinson Study Group. A controlled trial of Rotigotine monotherapy in early Parkinson's disease. Arch Neurol 2003;60:1721-1728.
23. Pâlhagen S, Heinonen EH, Hägglund J, et al. Selegiline delays the onset of disability in de novo parkinsonian patients. Neurology 1998;51:520-525.
24. Parkinson Study Group. A controlled trial of Rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol 2002;59:1937-1943.
25. Bonnet AM, Loria Y, Saint-Hilaire MH, Lhermitte F, Agid Y. Does long-term aggravation of Parkinson's disease result from nondopaminergic lesions? Neurology 1987;37:1539-1542.
26. Bejjani BP, Gervais D, Arnulf I, et al. Axial parkinsonian symptoms can be improved: the role of levodopa and bilateral subthalamic stimulation. J Neurol Neurosurg Psychiatry 2000;68:595-600.
27. Korczyn AD, Brooks DJ, Brunt ER, Poewe WH, Rascol O, Stocchi F, on behalf of the 053 Study Group. Ropinirole versus bromocriptine in the treatment of early Parkinson's disease: a 6-month interim report of a 3-year study. Mov Disord 1998;13:46-51.
28. Rascol O, Pathak A, Bagheri H, Montastruc JL. Dopaminagonists and fibrotic valvular heart disease: further considerations. Mov Disord 2004;19:1524-1525.